Skip to main content
AMRX
NASDAQ Life Sciences

Amneal to Acquire Kashiv BioSciences for $763M Upfront, Up to $1.1B Total, and Raises FY26 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$13.41
Mkt Cap
$4.153B
52W Low
$7.02
52W High
$15.42
52W Position info
91% above low
Off High info
13% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AMRX sits 91% above its 52-week low of $7.02.

Summary

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $762.9 million upfront, with potential for up to $1.1 billion including earnouts, to build a global biosimilars platform. The company also reported strong preliminary Q1 2026 results and raised its full-year guidance.


Key Events · M&A and Partnerships · AMRX

  • Definitive Acquisition Agreement

    Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC. The transaction includes $375 million in cash and 28,942,108 shares of Class A common stock, valued at approximately $387.9 million based on the current stock price. This totals $762.9 million in upfront consideration.

  • Significant Potential Earnouts

    The acquisition also includes potential contingent payments of up to $350 million upon the achievement of certain regulatory milestones for designated product candidates, plus potential contingent royalty payments over a 12-year period, bringing the total potential deal value to over $1.1 billion.

  • Strategic Rationale for Biosimilars

    The acquisition is a strategic move to establish a scaled, fully integrated global biosimilars platform, positioning Amneal to capitalize on a projected $300 billion+ global biologics loss-of-exclusivity opportunity over the next decade. It is expected to accelerate growth and diversify Amneal's long-term profile.

  • Preliminary Q1 2026 Financial Results

    Amneal reported strong preliminary Q1 2026 results, with consolidated net revenue of $723 million (up 4% year-over-year), net income of $78 million (up 217%), Adjusted EBITDA of $202 million (up 19%), and Adjusted diluted EPS of $0.27 (up 29%).


Analysis · AMRX · Life Sciences

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences, a strategic move to establish a fully integrated global biosimilars platform. The acquisition is valued at $375 million in cash and approximately $387.9 million in stock consideration (28,942,108 shares at $13.41/share), totaling $762.9 million upfront. Additionally, sellers are eligible for up to $350 million in contingent regulatory milestone payments and potential royalties, bringing the total potential value to over $1.1 billion. This transaction is highly strategic, aiming to capitalize on a projected $300 billion+ global biologics market opportunity over the next decade and diversify Amneal's long-term growth profile. The stock consideration represents approximately 9.07% dilution based on current outstanding shares. Concurrently, Amneal reported strong preliminary Q1 2026 results, with consolidated net revenue up 4% to $723 million and net income up 217% to $78 million. The company also raised its full-year 2026 guidance for Adjusted EBITDA, Adjusted diluted EPS, and Operating cash flow, signaling robust standalone performance. The combination of a significant strategic acquisition and positive financial performance is a strong market signal.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMRX was trading at $13.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $7.02 to $15.42. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRX - Latest Insights

AMRX
Nov 17, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $21.39 info
Change: +$0.270 (+1%) info
Market Cap: $7.453B info
AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.39 info
Change: +$0.110 (+0.52%) info
Market Cap: $7.453B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.39 info
Change: +$1.16 (+6%) info
Market Cap: $7.453B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.39 info
Change: +$1.19 (+6%) info
Market Cap: $7.453B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.39 info
Change: +$1.01 (+5%) info
Market Cap: $7.453B info